title: Anesthesia and myasthenia gravis.
abstract: Myasthenia gravis (MG) is a disease affecting the nicotinic acetylcholine receptor of the post-synaptic membrane of the neuromuscular junction, causing muscle fatigue and weakness. The myasthenic patient can be a challenge to anesthesiologists, and the post-surgical risk of respiratory failure has always been a matter of concern. The incidence and prevalence of MG have been increasing for decades and the disease is underdiagnosed. This makes it important for the anesthesiologist to be aware of possible signs of the disease and to be properly updated on the optimal perioperative anesthesiological management of the myasthenic patient. The review is based on electronic searches on PubMed and a review of the references of the articles. The following keywords were used: myasthenia gravis AND neuromuscular blocking agents, myasthenia gravis AND sevoflurane, myasthenia gravis AND epidural, myasthenia gravis AND neuromuscular blockade reversal and myasthenia gravis AND pyridostigmine. The articles included were from reviews and clinical trials written in English. MG patients can easily be anesthetized without need for post-surgery mechanical ventilation whether it is general anesthesia or peripheral nerve block. Volatile anesthesia or the use of an epidural for the patient makes it possible to avoid the use of neuromuscular blocking agents, and when used, it should be in smaller doses and the patient should be carefully monitored. This review shows that with thorough pre-operative evaluation, continuing the daily pyridostigmine and careful monitoring the MG patient can be managed safely.
authors.affiliation: Department of Anesthesiology, Sydvestjysk Sygehus Esbjerg, Denmark. louise@blichfeldtnet.dk
authors.forename: L
authors.initials: L
authors.lastname: Blichfeldt-Lauridsen
authors.forename: B D
authors.initials: BD
authors.lastname: Hansen
mesh_terms: D000758:Anesthesia; D000767:Anesthesia, Epidural; D018685:Anesthetics, Inhalation; D002800:Cholinesterase Inhibitors; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications* / Q000628:therapy; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D010149:Postoperative Pain / Q000188:drug therapy; D019990:Perioperative Care; D011182:Postoperative Care; D011300:Preoperative Care; D011729:Pyridostigmine Bromide; D012121:Respiration, Artificial; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000627:therapeutic use
chemical_list: D018685:Anesthetics, Inhalation; D002800:Cholinesterase Inhibitors; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D011729:Pyridostigmine Bromide